At the news
? NEUTRALIMPACT 3/10 6-K filed Sep 14, 2026 at 06:35 ET
Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepec, Morelos) between July 17 and September 8, 2026, issuing a Form FDA 2953 with two observations. The company will respond within the stipulated timeline. This is a routine regulatory follow-up with no material financial impact disclosed, and the two observations are not quantified or characterized as critical.
- USFDA conducted a records assessment under Section 704(a)(4) at Dr. Reddy's API facility in Mexico (Industrias Químicas Falcón de México, S.A. de C.V.) from July 17 to September 8, 2026.
- The USFDA issued a Form FDA 2953 containing two observations; the company will respond within the stipulated timeline.
- No warning letter, shutdown, import alert, or material financial impact was disclosed in the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access